ZOLEDRONIC ACID IN BONE METASTASES FROM BREAST CANCER

Download full text PDF
Issue: 
11
Year: 
2015

A. Snegovoy, Candidate of Medical Sciences; I. Kononenko, Candidate of Medical Sciences; Professor L. Manzyuk, MD; Professor V. Selchuk, MD N.N. Blokhin Russian Cancer Research Center, Moscow

The use of bone remodeling markers is of great importance for evaluating the efficiency of bone metastases in malignant tumors. It is a convenient and safe method that is essential for conducting clinical trials.
Keywords: 
breast cancer
bone metastases
osteomodifying agents
biphosphonates
P1NP
PINP

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Kohno N., Aogi K., Minami H. et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastasis from breast cancer: a randomised, placebo-controlled trial // J. Clin. Oncol. – 2005; 23: 3314–21.
  2. Saad F., Gleason D., Murray R. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer // J. Natl. Cancer Inst. – 2004; 96: 879–82.
  3. Apolihin O.I., Sivkov A.V., Oschepkov V.N. i dr. Effektivnost' zoledronovoj kisloty u bol'nyh s kostnymi metastazami raka predstatel'noj zhelezy. Prilozhenie k zhurnalu «Andrologija i genital'naja hirurgija». Materialy Mezhdunarodnogo kongressa po andrologii 28–31 maja 2009. Sochi, OK «Dagomys» UD Prezidenta RF.
  4. Kulieva I.E., Besova N.S. Opyt primenenija zoledronovoj kisloty (preparat Rezorba) dlja lechenija bol'nyh s kostnymi metastazami // Effektivnaja farmakoterapija. Onkologija, Gematologija i Radiologija. – 2012; 4.
  5. Lipton A., Cook R., Major P. et al. Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity // The Oncologist. – 2007; 12: 1035–43.
  6. Seibel M., Lang M., Geilenkeuser W.-J. Interlaboratory Variation of Biochemical Markers of Bone Turnover // Clin. Chem. – 2001; 47: 1443–50.
  7. Leeming D., Koizumi M., Qvist P. et al. Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers // Biomarkers in Cancer. – 2011; 3: 15–23.